Cadence Pharmaceuticals (Nasdaq: CADX ) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Cadence Pharmaceuticals beat expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP loss per share shrank. GAAP loss per share dropped.
Margins grew across the board.
Cadence Pharmaceuticals notched revenue of $23.6 million. The eight analysts polled by S&P Capital IQ expected a top line of $19.8 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $8.0 million.
EPS came in at -$0.13. The six earnings estimates compiled by S&P Capital IQ predicted -$0.14 per share. Non-GAAP EPS were -$0.13 for Q1 versus -$0.27 per share for the prior-year quarter. GAAP EPS were -$0.02 for Q1 versus -$0.27 per share for the prior-year quarter.
For the quarter, gross margin was 65.4%, much better than the prior-year quarter. Operating margin was -33.6%, much better than the prior-year quarter. Net margin was -5.8%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $23.1 million. On the bottom line, the average EPS estimate is -$0.11.
Next year's average estimate for revenue is $100.6 million. The average EPS estimate is -$0.34.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 69 members out of 107 rating the stock outperform, and 38 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give Cadence Pharmaceuticals a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cadence Pharmaceuticals is outperform, with an average price target of $6.38.
- Add Cadence Pharmaceuticals to My Watchlist.